Table 3: Grade of evidence

|  |
| --- |
| **Question: Should Colchicine be used for COVID-19?Bibliography:** Meta-analysis |
| **Quality assessment** | **Summary of Findings** |
| **Participants(studies)Follow up**  | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Publication bias** | **Overall quality of evidence** | **Study event rates (%)** | **Relative effect**(95% CI) | **Anticipated absolute effects** |
| **With Control** | **With Colchicine** | **Risk with Control** | **Risk difference with Colchicine** (95% CI) |
| **Clinical deterioration** (assessed with: Need for oxygen supplementation/ ICU care/ death) |
| 402(3 studies1) | serious | no serious inconsistency | no serious indirectness | no serious imprecision | reporting bias strongly suspected | ⊕⊕⊝⊝**LOW**due to risk of bias, publication bias | 60/208 (28.8%) | 22/194 (11.3%) | **OR 0.31** (0.18 to 0.54) | **Study population** |
| **288 per 1000** | **177 fewer per 1000**(from 109 fewer to 220 fewer) |
| **Moderate** |
|  | **-** |

|  |
| --- |
| **Development of adverse effect** (assessed with: Development of diarrhea (as it is the most common side effect with colchicine) and/or any other side effect leading to withdrawal of colchicine. ) |
| 402(3 studies1) | serious | no serious inconsistency | no serious indirectness | no serious imprecision | reporting bias strongly suspected | ⊕⊕⊝⊝**LOW**due to risk of bias, publication bias | 10/208 (4.8%) | 38/194 (19.6%) | **OR 5.31** (2.43 to 11.59) | **Study population** |
| **48 per 1000** | **163 more per 1000**(from 61 more to 321 more) |
| **Moderate** |
|  | **-** |

1 One observational study